PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,
|
|
|
- Alberta Floyd
- 5 years ago
- Views:
Transcription
1 11 th International Workshop on Peritoneal Surface Malignancy PRELIMINARY PROGRAM SEPTEMBER 9-11, 2018 Maison de la Chimie, Paris, France
2 9THSATURDAY 8TH 2SUNDAY Saturday, September 8 th 16h00-18h00 Registration Sunday, September 9 th 07h30 Registration 08h15 Welcome Remarks PH. Sugarbaker (USA) - O. Glehen (France) - D. Goéré (France) - M. Pocard (France) 08h30-12h15 Radiological consensus session Organizing: A. Dohan (France) - P. Rousset (France) 08h30 Colorectal and gastric free papers Chairmen: O. Glehen (France) - PH. Sugarbaker (USA) 09h20 In practice Chairmen: R. Lo Dico (France) - Y. Yonemura (Japan) 1. Intraperitoneal chemotherapy: indications in gastric peritoneal metastases Speaker: J. Kitayama (Japan) 2. PIPAC: How I do it? Speaker: M. Hübner (Switzerland) 09h50 Take home message Evaluation of histological response to preoperative chemotherapy Chairmen: F. Bibeau (France) - P. Sammartino (Italy) Speaker: W. Solass (Germany) 10h00 BREAK - VISIT POSTERS AND EXHIBITS 10h30 Free papers session - Best communications Chairman: L. Gladieff (France) 11h00 Recent results of the randomized clinical trials and futures for colorectal and gastric peritoneal metastases Chairmen: D. Goéré (France) - S. Gonzales Moreno (Spain) - V. Verwaal (Denmark) PRODIGE 7 - F. Quenet (France) PROPHYLOCHIP - D. Goéré (France) COLOPEC - PJ. Tanis (The Netherlands) COMBATAC - P. Piso (Germany) GASTRIPEC- B. Rau (Germany) GASTRTICHIP - O. Glehen (France) 12h15 LUNCH - VISIT POSTERS AND EXHIBITS
3 13h30 Satellite Symposium: Debates: Procedures for HIPEC: open/closed/laparoscopy Chairmen: J. Esquivel (USA) - M. Pocard (France) 1. Pro open: Speaker: D. Bartlett (USA) 2. Pro closed: Speaker: O. Glehen (France) sponsored by 14h30 Translational research and pre-clinical models for peritoneal disease Chairmen: I. De Hingh (The Netherlands) - M. Pocard (France) 1. Animal model for PIPAC Speaker: W. Ceelen (Belgium) 2. PMP4Cure an European network Speaker: K. Flatmark (Norway) 3. Prophylaxis of peritoneal tumoral implants Speaker: M. Pocard (France) 4. Free papers SUNDAY 9 TH 14h30 Selected videos Chairmen: A. Nissan (Israël) - C. Arvieux (France) 15h10 Take home message: Screening before HIPEC Chairmen: H. Cashin (Sweden) - P. Rousset (France) Speaker: C. Dromain (France) 15h30 Satellite Symposium 16h00 BREAK - VISIT POSTERS AND EXHIBITS 16h30 Pathology of peritoneal disease Organizing: F. Bibeau (France) - P. Dartigues (France) 16h30 Radiology and Translational Research - Free papers Chairmen: A. Dohan (France) - W. Ceelen (Belgium) 17h20 Keynote Lecture: BIG DATA - applications for clinical research Chairman: V. Verwaal (Denmark) Speaker: JM. Bereder (France) 17h45 Clinical cases from the less to the more experienced surgeons Chairmen: O. Sgarbura (France) - A. Bhatt (India) 3
4 Monday, September 10 th 07h00 Registration 07h30 Meet the professor 4MONDAY 10TH 1. CT assessment versus laparoscopic assessment of peritoneal metastases prior to CRS O. Glehen (France) - P. Rousset (France) - K. Van der Speeten (Belgium) 2. Laparoscopic HIPEC: indications? M. Alyami (France) - J. Esquivel (USA) - B. Rau (Germany) 3. Management of parietal defect R. Lo Dico (France) - D. Morris (Australia) - G. Passot (France) 4. Management of intraoperative hyperthermia V. Billard (France) - I. de Hingh (The Netherlands) - M. Pocard (France) 5. Pathology and peritoneal malignancies F. Bibeau (France) - N. Carr (USA) - W. Solass (USA) 08h30 Peritoneal primary malignancies - Free papers Chairmen: EA. Levine (USA) - B. Moran (UK) 09h20 In practice Chairmen: J. Esquivel (USA) - D. Morris (USA) 1. New classification for peritoneal pseudomyxoma Speaker: P. Dartigues (France) 2. LAMN, surveillance or HIPEC? Speaker: J. Baumgartner (USA) 09h50 Take home message and vote Towards a consensus for treatment of non resectable malignant peritoneal mesothelioma Chairmen: M. Deraco (Italy) - G. Freyer (France) Speaker: M. Ducreux (France) 10h15 BREAK - VISIT POSTERS AND EXHIBITS 10h45 Consensus statement for Peritoneal Mesothelioma and Pseudomyxoma peritonei 11h15 Recent results of the randomized clinical trials and futures for primary malignancies Chairmen: D. Baratti (Italy) - B. Moran (UK) - F. Quenet (France) 12h15 LUNCH - VISIT POSTERS AND EXHIBITS
5 13h30 Satellite Symposium 14h30 Anesthesiology and intensive care for HIPEC Chairmen: E. Gayat (France) - V. Billard (France) 14h30 Selected videos Chairmen: C. Eveno (France) - J. Ferreira Loureiro (Brazil) 5MONDAY 10TH 15h10 Debates about pre - and / or post systemic chemotherapy associated to HIPEC for colorectal peritoneal metastases Chairmen: B. Rau (Germany) - Y. Li (China) 1. Pro systemic chemotherapy Speaker: C. Eveno (France) 2. Contra systemic chemotherapy Speaker: I. De Hingh (The Netherlands) 15h40 Take home message: Management of per and postoperative intraperitoneal bleeding Chairmen: C. Brigand (France) - P. Piso (Germany) Speaker: PH. Sugarbaker (USA) 16h00 BREAK - VISIT POSTERS AND EXHIBITS 16h30 Intraperitoneal Drugs and Pharmacology Chairmen: N. Bakrin (France) - K. Van der Speeten (The Netherlands) 16h30 Anesthesia Early recovery Preoperative preparation Nutrition Free papers Chairmen: G. Passot (France) F. Mohamed (UK) 17h10 Satellite Symposium: Debates: Hyperthermia: yes or not? Chairmen: I. de Hingh (The Netherlands) - F. Quenet (France) 1. Pro hyperthermia: Speaker: D. Morris (Australia) 2. Contra hyperthermia: Speaker: W. Ceelen (Belgium) 17h45 Clinical cases from the less to the more experienced surgeons Chairmen: JB. Delhorme (France) - M. Gelli (France) 20h00 CONGRESS BANQUET
6 NURSING AND ALLIED HEALTH SESSIONS DAY 08h h45 Invited conference Cytoreductive surgery and HIPEC: current indications and issues 09h15 Free session 1: Modalities of IP chemotherapy and the related current issues 10h15 BREAK - VISIT POSTERS AND EXHIBITS 10h45 Round table 1: The nurse in the OR: education practices all around the globe 6MONDAY 10TH 11h30 Free session 2: Allied professionals roles and peritoneal carcinomatosis treatment 12h15 LUNCH - VISIT POSTERS AND EXHIBITS 13h30 Invited conference Checklist and prevention of accidents in the operative room 14h15 Free session 3: The management of HIPEC patients in the OR 15h00 Round table 2: Caregivers and working environment safety: practices around the globe 16h00 BREAK - VISIT POSTERS AND EXHIBITS 16h30 Free session 4: PIPAC new challenges in the OR and in the surgery department 17h30 CLOSING REMARKS: THE ORGANIZING COMMITTEE ORGANIZERS OF BEIJING 2020
7 Tuesday, September 11 th 07h00 Registration 07h30 Meet the professor 7TUESDAY 11TH 1. How to set up a national HIPEC program (Instances and registries) A. Bhatt (India) - F. Dumont (France) - C. Quadros (Brazil) 2. How to set up a national PIPAC program N. Bakrin (France) - M. Hübner (Switerland) - C. Tempfer (Germany) 3. New technology to detect non visible peritoneal deposits (indocyanine green ) J. Esquivel (USA) - M. Gelli (France) - G. Liberale (Belgium) 4. Requirement for stoma after complete pelvic peritonectomy with rectosigmoid colon resection and HIPEC C. Arvieux (France) - O. Glehen (France) - PH. Sugarbaker (USA) 5. Enhanced recovery and HIPEC D. Goéré (France) - F. Mohamed (UK) - G. Passot (France) 08h30 Peritoneal carcinomatosis from ovarian carcinoma free papers Chairmen: N. Bakrin (France) - A. Fagotti (Italy) 09h20 Controversial on the randomized clinical trials and futures for HIPEC in peritoneal carcinomatosis from ovarian cancer Chairmen: JM. Classe (France) - G. Freyer (France) - J. Spiliotis (Greece) HIPEC as standard or optional in first line treatment Pro: WJ. Van Driel (The Netherlands) Contra: G. Freyer (France) HIPEC as standard or optional in platine sensitive recurrence Pro: J. Spiliotis (Greece) Contra: A. Fagotti (Italy) HIPEC as standard or optional in platine resistant recurrence Pro: N. Bakrin (France) Contra: JM. Classe (France) 10h35 Award ceremony 10h45 BREAK - VISIT POSTERS AND EXHIBITS 11h15 Timing of surgery in peritoneal carcinomatosis from ovarian carcinoma Chairman: A. Fagotti (Italy) Speaker: DS. Chi (USA) 11h40 Free papers from clinical trials and futures for PIPAC Chairmen: M. Pocard (France) - M. Reymond (Germany) 12h45 Beijing PSOGI h00 END OF THE MEETING
Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Frédéric Bibeau, Caen University
Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Salah-Eddin Al-Batran, Institut für Klinisch-Onchologische
Welcome Address. Symposium Chairmen. Dear friends and colleagues,
Welcome Address Dear friends and colleagues, It is a great pleasure for us to announce the organization of the PSOGI International Symposium on Advanced Ovarian Cancer which will be held in Athens, Greece
Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK
Chairs Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK Faculty members Andreas Brandl, Charité Campus Berlin, Berlin, DE James Coakes,
10 th International Congress on Peritoneal Surface Malignancies
10 th International Congress on Peritoneal Surface Malignancies November 17 19, 2016 Omni Shoreham Hotel Washington, DC Course Director: MedStar Washington Hospital Center Washington, DC www.psogi2016.com
FINAL SCIENTIFIC PROGRAMME
FINAL SCIENTIFIC PROGRAMME AGENDA Day 1 Speaker Chairpersons 8:30 AM 8:45 AM 8:45 AM 9:00 AM Intraperitoneal chemotherapytypes, techniques, tips Choice of drugs and carrier solutions for intraperitoneal
CURRICULUM VITAE 2005
CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr
Results of a French Multicentric Analysis
Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
Department of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2
Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
How to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS)
Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS) 19-21 MARCH 2015 HAMBURG EUROPEAN SCHOOL OF PERITONEAL SURFACE ONCOLOGY Management of Hyperthermic Intraperitoneal
Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
POLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP278 Section: Medical Benefit Policy Subject: Hyperthermia in Cancer Therapy (e.g., HIPEC) I. Policy: Hyperthermia in Cancer Therapy (e.g., HIPEC) II. Purpose/Objective:
Gastric cancer treated with pressurized intraperitoneal aerosol chemotherapy: revising an option for peritoneal carcinomatosis
Macedo et al. J Cancer Metastasis Treat 2018;4:8 DOI: 10.20517/2394-4722.2017.72 Journal of Cancer Metastasis and Treatment Original Article Open Access Gastric cancer treated with pressurized intraperitoneal
International scientific-practical conference «Management of Peritoneal Surfaces Malignancy» Irkutsk, August 9-11, Program
Day 1 Program Wednesday, 9 of August, 2017 Regional Oncology Center, Irkutsk Conference Hall 8.00-8.30 Registration of participants 8.30-8.50 Opening conference Welcome Gouverneur (Sergey Levchenko) Welcome
Rationale for the treatment. Peritoneal Surface Malignancy
Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten 05/10/12 A full circle :acknowledgements Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten
U T C H. No disclosure
D U GOG T C H Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer: OVHIPEC-2 Willemien van
Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
CRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017
CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
Vassos et al. World Journal of Surgical Oncology (2016) 14:42 DOI 10.1186/s12957-016-0804-x RESEARCH Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal (HIPEC) in patients with recurrent
MP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
Computerized System for Staging Peritoneal Surface Malignancies
Ann Surg Oncol (2016) 23:1454 1460 DOI 10.1245/s10434-015-4966-5 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Computerized System for Staging Peritoneal Surface Malignancies Paolo Sammartino, MD, PhD, Daniele
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
Pre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4251/wjgo.v6.i10.407 World J Gastrointest Oncol 2014 October 15; 6(10): 407-412 ISSN 1948-5204
Heated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/heated-intraperitonealchemotherapy-hipec-for-advanced-abdominal-cancers/7091/
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
HIPEC AND COMPLICATED COLORECTAL SURGERY
HIPEC AND COMPLICATED COLORECTAL SURGERY START: May 16th, 2014 END: May 17th, 2014 LOCATION: Vilnius, Lithuania OFFICIAL LANGUAGE: English Translation services will not be provided CERTIFICATION: Vilnius
Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Ann Surg Oncol (2013) 20:4224 4230 DOI 10.1245/s10434-013-3145-9 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch
Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting
Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
Journal of Gastrointestinal Surgery (2018) 22:884 893 https://doi.org/10.1007/s11605-017-3661-1 ORIGINAL ARTICLE Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center
Treatment of peritoneal metastases from colorectal cancer
Gastroenterology Report, 3(4), 2015, 298 302 doi: 10.1093/gastro/gov044 Advance Access Publication Date: 30 September 2015 Review REVIEW Treatment of peritoneal metastases from colorectal cancer Loreen
All along the colon: multimodality imaging and staging
Satellite Symposium ESGAR 2011 All along the colon: multimodality imaging and staging Chairman: Prof. T. Lauenstein (Essen Germany) Invitation Sunday, May 22 nd, 2011 13:00-14:00 Venice Convention Centre,
ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2018) 25:
Ann Surg Oncol (2018) 25:1184 1192 https://doi.org/10.1245/s10434-018-6369-x ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14
1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011
International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic
This is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.
Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin
Gastroenterology Research and Practice Volume 2012, Article ID 981245, 5 pages doi:10.1155/2012/981245 Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma
Surgical Oncology, Mercy Medical Center, Baltimore, MD
Ann Surg Oncol (2012) 19:110 114 DOI 10.1245/s10434-011-1840-y ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients
Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
Correspondence should be addressed to David Morris; Received 17 February 2013; Revised 14 April 2013; Accepted 24 June 2013
International Surgical Oncology Volume 2013, Article ID 461041, 5 pages http://dx.doi.org/10.1155/2013/461041 Research Article Quality of Life Study following Cytoreductive Surgery and Intraperitoneal
IJC International Journal of Cancer
IJC International Journal of Cancer Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors Irene Thomassen 1,2, Yvette R. van Gestel 2, Bert van Ramshorst
Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal
Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
Colorectal peritoneal metastases and IMPACT
Colorectal peritoneal metastases and IMPACT Vicki Pleavin-Evans Peritoneal Malignancy Clinical Nurse Specialist PMI Basingstoke Basingstoke and North Hampshire Hospital Aldermaston Road, Basingstoke, Hampshire
International Journal of Hyperthermia. ISSN: (Print) (Online) Journal homepage:
International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://www.tandfonline.com/loi/ihyt20 Drugs, doses, and durations of intraperitoneal chemotherapy: standardising
Made available by Hasselt University Library in Document
Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Link
COURSES ENDORSEMENT AND ACCREDITATION
COURSES ENDORSEMENT AND ACCREDITATION This course is organized in partnership with ESGO. This course meets the guidelines established in the "SAGES Framework for Post-Residency Surgical Education and Training"
Optimal drugs for HIPEC in different tumors
JBUON 2015; 20 (Suppl. 1): S40-S46 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Optimal drugs for HIPEC in different tumors Eelco de Bree Department
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis
JBUON 2017; 22(6): 1547-1553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Corporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
Appendix adenocarcinomas are rare and heterogeneous
ORIGINAL CONTRIBUTION Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma Omer Aziz, Ph.D., F.R.C.S. 1,2 Ihab Jaradat, F.R.C.S. 1 Bipasha
Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
6 th MD ANDERSON INTERNATIONAL MEETING IN EMBRACING NEW STANDARDS OF CARE IN GYNECOLOGIC CANCERS PRELIMINARY PROGRAM. Meeting Directors:
6 th MD ANDERSON INTERNATIONAL MEETING IN EMBRACING NEW STANDARDS OF CARE IN GYNECOLOGIC CANCERS Madrid, 9 th -11 th May, 2018 PRELIMINARY PROGRAM Meeting Directors: Registrations: www.mdanderson.es/embracingnewstandards
Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results
International Scholarly Research Network ISRN Surgery Volume 2011, Article ID 529876, 6 pages doi:10.5402/2011/529876 Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced
is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry
International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://tandfonline.com/loi/ihyt20 Treading the beaten path with old and new obstacles: a report from
Version 1.11 of 20/07/2018
Version 1.11 of 20/07/2018 NICE JANUARY 17-19, 2019 6 th International Workshop on Lung Health New approaches to respiratory diseases PRESIDENTS: F. BLASI, G.W. CANONICA CHAIRMEN: S. CENTANNI, J.C. VIRCHOW,
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal K. Van der Speeten, MD, PhD Pretoria 08/10/16 2016 : the Good, the Bad and the Ugly Chemosurgery The surgery in chemosurgery
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal
MP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
( Dedrick et al 1978 ) ( Armstrong et al 2006 )
( Dedrick et al 1978 ) ( Armstrong et al 2006 ) ( Dalh O et al 1999 ) ( Hahn GM et al 1983 ) ( G. Multhoff et al 1996 ) ( Helm CW et al 2010 ) ( de Bree E. et al 2015 ) ( Spiliotis J et al. et al
Surgical Department, Didimotichon General Hospital, Didimotichon, Greece 2
Hindawi Publishing Corporation Journal of Oncology Volume 22, Article ID 35834, 6 pages doi:.55/22/35834 Clinical Study Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy
Current Techniques in the Treatment of Severe Endometriosis
in the Treatment of Severe Endometriosis September 5 th to 7 th, 2011 Director: A. Wattiez France Faculty: J. Alcocer Mexico S. Barata Portugal M. Canis France J. Dequesne Switzerland H. Ferreira Portugal
30 th European Heart Diseases and Heart Failure Congress
30 th European Heart Diseases and Heart Failure Congress February 18-19, 2019 - Amsterdam, Netherlands Introduction: I t is a great pleasure and an honour to extend to you a warm invitation to attend the
Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.
Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites. Dr. Pere Bretcha Boix Plataforma de Oncología Hospital quironsalud Torrevieja 1 20-year survival of 70% 2 Appendiceal Neoplasms
Care, 4 University of North Dakota, 5 Christiana Care Health System, 6 UMass Memorial Medical Center,
The American Society of Peritoneal Surface Malignancies consensus on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States Esquivel
COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol (2011) 18:1052 1059 DOI 10.1245/s10434-010-1415-3 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal
5 th International Video Workshop
Sponsorship and Exhibition Prospectus 5 th International Video Workshop on Radical Surgery in Gynaecological Oncology April 21-23, 2016 Prague Czech Republic Dear business partners, It is my great pleasure
Kathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
Clinicopathological features and prognosis of pseudomyxoma peritonei
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 185-190, 2014 Clinicopathological features and prognosis of pseudomyxoma peritonei HUAN WANG 1*, XUEJUN WANG 2*, YANFANG JU 1, JINLIANG WANG 1, XIN ZHANG 1, YAO
Short-term Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Preliminary Analysis of a Multicentre Study
Short-term Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Preliminary Analysis of a Multicentre Study ANTONIO MACRÌ 1, VINCENZO ARCORACI 2, VALERIO BELGRANO 3, MARINA CALDANA
Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?
doi:10.21873/anticanres.11915 Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter? ARTURAS SUKOVAS 1*, VAIDOTAS CESNA 2,3*, ALDONA JASUKAITIENE 3, GIEDRIUS BARAUSKAS
Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS
Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS Department of surgical oncology, Carl von Hess hospital, Hammelburg, Germany www.klinik-hammelburg.de
Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review past, present and future
Review Article Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review past, present and future Ahmed Dehal 1 *, J. Joshua Smith 2 *, Garrett M. Nash 2 1 Kaiser Permanente, Fontana,
Gastrointestinal Oncology
2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting
Abstract EDITORIAL Madrid, Spain. Telephone:
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v23.i3.377 World J Gastroenterol 2017 January 21; 23(3): 377-381 ISSN 1007-9327 (print)
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
Purpose. Page 2 of 24
Accuracy of MDCT in the preoperative definition of peritoneal cancer index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC)
Information for health professionals - pseudomyxoma peritonei
Colorectal and peritoneal oncology centre Information for health professionals - pseudomyxoma peritonei What is it? Pseudomyxoma Peritonei (PMP) is often a slowly progressive disease that produces extensive
TGH Annual Report (2016) Editorial Office
TGH Annual Report (2016) Editorial Office tgh@amegroups.com Outline of the Report 1.Basic Information 2.Editor-in-Chief 3.Message from the EIC 4.Distribution of Editorial Board Members 5.Number of Published
Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations
JBUON 2014; 19(2): 549-553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional
Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer
Cashin et al. BMC Cancer 2013, 13:435 RESEARCH ARTICLE Open Access Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer Peter H Cashin
Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer
JBUON 2018; 23(2): 482-487 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic
Peritoneal carcinomatosis cytoreductive surgery and. HIPEC - overview and basics
Peritoneal carcinomatosis 1 Peritoneal carcinomatosis cytoreductive surgery and HIPEC - overview and basics BJÖRN L.D.M. BRÜCHER, MD, PhD, FACS, FRCS (Engl.) 1, POMPILIU PISO, MD, 2 VIC VERWAAL, MD, 3
Allied Health: Sustainable Integrated Health Care for all Australians
Allied Health: Sustainable Integrated Health Care for all Australians Catherine Turnbull Chief Allied and Scientific Health Advisor SA Health Presentation to Indigenous Allied Health Australia Conference,
VENUE. NMI Natural and Medical Sciences Institute at the University of Tübingen. Markwiesenstrasse 55, Reutlingen, Germany
VENUE NMI Natural and Medical Sciences Institute at the University of Tübingen Markwiesenstrasse 55, 72770 Reutlingen, Germany GPS-Coordinate: 48 29 38.24 N 9 08 02.73 O AGENDA Get updated about latest
News Letter. Thanks letter AOCC2014. Asian Organization for Crohn s and Colitis. Vol.1 - Issue 1. Dear Colleagues, Dear Participants,
Vol. - Issue Thanks letter AOCC04 Dear Colleagues, Dear Participants, On behalf of the Governing Board, I would like to express my appreciation for your dedicated participation on The Second Annual Meeting